Text Size

Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

This study has been completed.
Sponsor:
Information provided by:
Alberta Health Services
ClinicalTrials.gov Identifier:
NCT00279721
First received: January 18, 2006
Last updated: January 18, 2012
Last verified: July 2011
History of Changes
  Purpose

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.


Condition Intervention Phase
Thyroid Neoplasms
 Procedure: IMRT
 Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study of Intensity-modulated Radiation (IMRT)With Simultaneous Integrated Boost (SIB) as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.

Resource links provided by NLM:

Drug Information available for: Thyroid
U.S. FDA Resources

Further study details as provided by Alberta Health Services:

Primary Outcome Measures:
  • toxicity according to RTOG criteria
  • locoregional control

Estimated Enrollment: 40
Study Start Date: January 2006
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Detailed Description:

Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • resected well-differentiated throid cancer with at least one high risk feature for locoregional recurrence

Exclusion Criteria:

  • medullary or anaplastic thyroid cancer, unresectable
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00279721

Sponsors and Collaborators
Alberta Health Services
Investigators
Principal Investigator: Harold Lau, MD Tom Baker Cancer Centre
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00279721     History of Changes
Other Study ID Numbers: 18916
Study First Received: January 18, 2006
Last Updated: January 18, 2012
Health Authority: Canada: Health Canada

Keywords provided by Alberta Health Services:
thyroid neoplasms
intensity modulated radiation
radiotherapy

Additional relevant MeSH terms:
Neoplasms
Thyroid Neoplasms
Thyroid Diseases
Endocrine Gland Neoplasms
 Neoplasms by Site
Head and Neck Neoplasms
Endocrine System Diseases

ClinicalTrials.gov processed this record on May 19, 2013